ICVX Icosavax
WatchlistIcosavax News
Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's Is How to Trade
Ross Stores Reports Strong Earnings, Joins Buckle, Twist Bioscience And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly lower, with the Dow Jones falling over 20 points on Friday. Shares of Ross Stores, Inc. (NASDAQ:ROST) surged during Friday's session as the company reported upbeat results fo
Guggenheim Initiates Coverage On Icosavax With Buy Rating, Announces Price Target of $28
Guggenheim analyst Seamus Fernandez initiates coverage on Icosavax with a Buy rating and announces Price Target of $28.
Icosavax Insiders Forfeit On 41% Gains After Selling Stock
While Icosavax, Inc. (NASDAQ:ICVX) shareholders have had a good week with the stock up 41%, insiders can't say the same having sold stock over the past year. The value of their investment would have
Express News | Icosavax Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
Target Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining more than 100 points on Wednesday. Shares of Target Corporation (NYSE:TGT) jumped during Wednesday's session after the company reported better-tha
TD Cowen Keeps Their Buy Rating on Icosavax (ICVX)
Icosavax Q3 Net Loss Narrows
Icosavax (ICVX) reported a Q3 net loss late Tuesday of $0.44 per diluted share, narrower than a loss of $0.55 a year earlier.
Icosavax Q3 EPS $(0.44) Beats $(0.57) Estimate
Icosavax (NASDAQ:ICVX) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.57) by 22.81 percent. This is a 20 percent increase over losses of $(0.55) per sh
Icosavax to Participate in the Jefferies London Healthcare Conference
SEATTLE, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agai
Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines agai
Oppenheimer Reiterates Outperform on Icosavax, Maintains $25 Price Target
Oppenheimer analyst Hartaj Singh reiterates Icosavax (NASDAQ:ICVX) with a Outperform and maintains $25 price target.
Icosavax Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 10/02/2023 222.58% Oppenheimer → $25 Reiterates Outperform → Outperform 04/25/2023 248.39% Oppenheimer → $
Analysts Offer Insights on Healthcare Companies: Icosavax (ICVX), Viatris (VTRS) and MoonLake Immunotherapeutics (MLTX)
We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, Icosavax (NASDAQ:ICVX) shareholders have done very well over the last year, with the share price soaring
Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines aga
RSV Vaccine Sales for Elderly Expected to Top $10B by 2030 in G7 Nations
Icosavax GAAP EPS of -$0.59
Jefferies Reaffirms Their Buy Rating on Icosavax (ICVX)
Icosavax Q2 EPS $(0.59) Beats $(0.60) Estimate
Icosavax (NASDAQ:ICVX) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.60) by 1.67 percent. This is a 3.51 percent decrease over losses of $(0.57) per s